More than 2,500 human miRNAs are potentially significant biomarkers. Moreover, the use of blood circulating miRNAs as disease-specific biomarkers is one of the most valuable outputs for translational and clinical research. Nevertheless, such an analysis still requires the selection of robust technologies, huge R&D work and reproducibility studies.
During the latest AACR Meeting (April 2015, Philadelphia – USA), Nadia Normand, R&D manager at tebu-bio’s laboratories (Le Perray en Yvelines, France), presented a poster comparing various platforms for measuring circulating miRNAs. It was the opportunity to further demonstrate the robustness of the miRNA 3D-Gene® microarray-based platform (Toray Industries).
To know more about the comparison, follow this link to access to the poster:
